Per the 10Q there are over 7 Million shares from warrants out that have an exercise price between $2.75-$3.40. Some may be hedged with Call Options sold against them.
They will put any cash they do not need to buying down the outstanding debt. I suspect if they retire it all they will definitely come out of the dark.
Point being that Boards of Directors today do not seem to be doing the correct things for their shareholders. Not the complete nonsense in your posts.
For anyone that missed it. Carl Icahn did an interview discussing Boards of Directors as it relates to the Family Dollar merger/buyout. You can see it on the CNBC web site. I believe what he says is pertinent for this company.
So I guess Avastin does not work and all the money being made from treating patients with Avastin is a figment of investors imagination?
Yep, any analyst or investor or institution should always look at the cash flow. The value of any company is the present value of its future cash flows.
The two mechanisms of action certainly seem to be very complimentary. Kill the tumor, stop it from growing back.
Chemo by itself has a shorter median PFS than Avastin by itself. So using percentages is very misleading, ie if you add to Avastin to Chemo a percentage increase will look more impressive than adding CA4P to Avastin since you start with a longer PFS in the second case.. You need to look at the actual length of median time for PFS in each study.
Also it is likely you could try one treatment and at progression try the second, and then even try all three combined, after progression in both regimens. The fact that CA4P enhances PFS when combined with Avastin adds a lot of possibilities.
What are you talking about.
He filed a 13G in August 2013 that he owned 944,000 shares of TKRM. At that time the stock had been trading between 4-6 for over 6 months. He had to file within 45 days of the end of the year so he amended it in Feb 2014 reflecting his holdings as of 12/31/2013.
I think you are misreading the 10Q. According to the separation contract (ex 10.3) he received one years pay plus COBRA. That was $386,250.00 plus COBRA, (total $435,000). The 10Q says this amount was accrued ($435,000) as an accrued expense expense and $387,000 of it remained. So it looks as if it was a "resignation" in name only but he received what he was contractually due to received if dismissed without cause.
Data for the Avastin trial is already known. It is not really comparable in terms of percent increase since in the trial it is Avastin plus Cheno over Chemo (ie the improvement of adding Avastin to Chemo). To be comparable in terms of percent it would need to be Avastin Plus Chemo over Avastin (the improvement of add ing Chemo to Avastin) since the GOG trial was CA4P plus Avastin over Avastin (the improvement of adding CA4P to Avastin).
Buyers of secondary certainly short prior to the secondary. I simply do not understand why they would short instead of simply selling shares. They need to pay to short and they still own the shares they gain absolutely nothing over simply selling the shares. Makes no sense, they get cash if they sell shares. It is not like they are committed to a holding period as in some secondaries. Sorry, it simply makes no sense.
First the buyers in the secondary have a lot of shares so why would they short? If they did anything they would sell the shares. So why would they sell the shares for a loss. They would need to believe they could sell the shares from the warrants at the loss plus the exercise price, ie prices significantly higher than the present price. While it is possible that they would sell it down, I expect they would then buy it back up. IE they would act just like any trader.
One problem with that is if you did it in March of this year you would have missed the opportunity to sell for over 120% in profits. Certainly you may end up being right but then again there is always a risk they will announce a partnership tomorrow. So certainly those who have bought over the last month have lost money short term, of course if you average in then you might still be buying down here.
In any case playing for 20-30 cents down here does not make a lot of sense if you believe that their results will give significant upside. If you do not believe it then of course you should not be buying.
Votrient has been pushed back, but it really has nothing to do with money especially since it will be done by a non-profit as was the Avastin trial. I am pretty sure that it has to do with the change of hands of the Votrient IP and the need for a contract to supply the drug.
I don't know about GNET but then again imo they should not be spending money on early stage trials at this point.
I could be very wrong but I suspect there will not be an offering until at least after trial results since I believe they have sold all of the shelf and the usual suspects have a full bag of shares.
Past the results I have no idea what will happen but I suspect anyone buying here will make good money on the results!
But you just said the only thing that makes sense is that the test results this fall will be bad. Looks as if you are simply posting nonsense in order to buy at a lower price. Good Luck.